Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 9/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774437 | 0.95 | EHMT2 (0.55) | EHMT2SSTR5HRH1HTR2BKDM1A | |
| SCHEMBL3775638 | 0.93 | SSTR5 (0.55) | EHMT2SSTR5HRH1HTR2BKDM1A | |
| SCHEMBL4234177 | 0.90 | EHMT2 (0.51) | EHMT2SSTR5HRH1HTR2BKDM1A | |
| SCHEMBL3779044 | 0.90 | EHMT2 (0.54) | EHMT2SSTR5HRH1HTR2BKDM1A | |
| SCHEMBL3775880 | 0.90 | SSTR5 (0.57) | EHMT2SSTR5KDM1ARCOR1TLR7 | |
| SCHEMBL3779098 | 0.89 | EHMT2 (0.55) | EHMT2SSTR5KDM1ARCOR1TLR7 | |
| SCHEMBL3776962 | 0.89 | SSTR5 (0.57) | EHMT2SSTR5KDM1ARCOR1TLR7 | |
| SCHEMBL3781168 | 0.89 | EHMT2 (0.51) | EHMT2SSTR5HRH1HTR2BKDM1A | |
| SCHEMBL3778510 | 0.88 | EHMT2 (0.56) | EHMT2SSTR5HRH1HTR2BKDM1A | |
| SCHEMBL3775626 | 0.88 | EHMT2 (0.56) | EHMT2SSTR5HRH1HTR2BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | EHMT2 4728/4885SSTR5 1/4885HRH1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.